Evolving Therapies in Gynecological Oncology: From Chemotherapy to Personalized Medicine

The field of gynecological oncology has undergone significant transformations over the past few decades. Historically, the management of gynecological cancers, including cervical, ovarian, and endometrial cancers, heavily relied on traditional chemotherapy regimens. Agents such as carboplatin and paclitaxel became standard treatments, especially for advanced stages of cancer. Despite the initial efficacy, these treatments often came with severe side effects and a lack of specificity, prompting the search for more refined approaches. Recent years have seen a surge in the understanding of cancer biology, leading to the development of targeted therapies and immunotherapies. The approval of drugs that specifically target molecular anomalies within tumors, such as mismatch repair deficiencies, has paved the way for chemo-free treatment protocols, representing a remarkable shift in cancer therapy.

This Research Topic aims to explore the evolution from conventional chemotherapy to modern, personalized therapeutic strategies in gynecological oncology. The focus will be on examining past and present treatment paradigms, analyzing the stride towards individualized care, and shedding light on current challenges and future potential advancements in the field. The objective is to address questions such as the impact of molecular classification on treatment decisions, the effectiveness of new therapies compared to traditional methods, and the barriers to implementing personalized medicine widely.

To gather further insights in advancing gynecological oncology treatments, we welcome articles addressing, but not limited to, the following themes:
o Historical perspectives on chemotherapy in gynecological cancers
o Case studies on successful targeted therapy applications
o The role of molecular diagnostics in treatment planning
o Comparative analysis of traditional vs. modern treatment outcomes
o Barriers and facilitators to adopting personalized medicine in clinical settings

This Research Topic encourages submissions of various article types, including original research, reviews, and case reports, that contribute to broadening knowledge and driving innovation in gynecological oncology.




Please note that manuscripts consisting solely of bioinformatics or computational analysis of public omics databases that are not supplemented by relevant functional validation (clinical cohort or biological validation, in vitro or in vivo) are out of scope for this Research Topic.

Article types and fees

This Research Topic accepts the following article types, unless otherwise specified in the Research Topic description:

• Brief Research Report
• Case Report
• Clinical Trial
• Editorial
• FAIR² Data
• FAIR² DATA Direct Submission
• Hypothesis and Theory
• Methods
• Mini Review
• ... View all formats

Articles that are accepted for publication by our external editors following rigorous peer review incur a publishing fee charged to Authors, institutions, or funders.

Article types

This Research Topic accepts the following article types, unless otherwise specified in the Research Topic description:

• Brief Research Report
• Case Report
• Clinical Trial
• Editorial
• FAIR² Data
• FAIR² DATA Direct Submission
• Hypothesis and Theory
• Methods
• Mini Review
• Opinion
• Original Research
• Perspective
• Review
• Specialty Grand Challenge
• Systematic Review
• Technology and Code

Keywords: endometrial cancer, ovarian cancer, cervical cancer, immunotherapy, ADC, target-therapy, mechanism of resistance, predictive biomarkers

Important note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.